1cP-AL-LAD

Last updated

1cP-AL-LAD
1CP-AL-LAD structure.png
Clinical data
Routes of
administration 		Oral
Drug class Serotonergic psychedelic; Hallucinogen
Identifiers
  • (6aR,9R)-4-(cyclopropanecarbonyl)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H31N3O2
Molar mass 417.553 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@@H]1C=C2[C@@H](Cc3cn(C(=O)C4CC4)c4cccc2c34)N(C1)CC=C
  • InChI=1S/C26H31N3O2/c1-4-12-28-15-19(25(30)27(5-2)6-3)13-21-20-8-7-9-22-24(20)18(14-23(21)28)16-29(22)26(31)17-10-11-17/h4,7-9,13,16-17,19,23H,1,5-6,10-12,14-15H2,2-3H3/t19-,23-/m1/s1
  • Key:VSABTUDYQCMWKE-AUSIDOKSSA-N

1cP-AL-LAD is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). [1] [2] It is thought to act as prodrug of AL-LAD. [2]

Contents

Interactions

Chemistry

Analogues

Related compounds include 1cP-LSD, 1D-LSD, 1P-AL-LAD, and 1T-AL-LAD, among others.

History

1cP-AL-LAD has been sold as a designer drug. [1] It was first identified in France in June 2021. [1]

See also

References

  1. 1 2 3 Morais J, Evans-Brown M, Gallegos A, Christie R, Jorge R, Planchuelo G, et al. (2022-09-01). "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System" . Toxicologie Analytique et Clinique. 30th meeting of SFTA- 59th meeting of TIAFT - September 2022. 34 (3, Supplement): S29 –S30. Bibcode:2022ToxAC..34S..29M. doi:10.1016/j.toxac.2022.06.022. ISSN   2352-0078.
  2. 1 2 Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Stratford A, Auwärter V, et al. (March 2023). "Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities". Drug Test Anal. 15 (3): 277–291. doi:10.1002/dta.3397. PMID   36321499.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.